ArticleGut2002
Aberrant P-cadherin expression is an early event in hyperplastic and dysplastic transformation in the colon.
Article in Gut, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 66 citations in OpenAlex.
- Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer.Oncogene · 2002Trial
- Microenvironment-induced restoration of cohesive growth associated with focal activation of P-cadherin expression in lobular breast carcinoma metastatic to the colon.The journal of pathology. Clinical research · 2024Article
- The Gengnianchun recipe attenuates insulin resistance-induced diminished ovarian reserve through inhibiting the senescence of granulosa cells.Frontiers in endocrinology · 2023Article
- Dual role of E-cadherin in cancer cells.Tissue barriers · 2022Review
- Article
- A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DARTThe AAPS journal · 2019Article
- Cadherin Signaling in Cancer: Its Functions and Role as a Therapeutic Target.Frontiers in oncology · 2019Review
- Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease.PloS one · 2019Article
- Blood serum levels of E-cadherin in patients with colorectal cancer.Przeglad gastroenterologiczny · 2017Article
- Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells.International journal of molecular sciences · 2016Review
- Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer.Antibodies (Basel, Switzerland) · 2016Article
- Induction of KIAA1199/CEMIP is associated with colon cancer phenotype and poor patient survival.Oncotarget · 2015Article
- P-cadherin and the journey to cancer metastasis.Molecular cancer · 2015Review
- Expression changes of cell-cell adhesion-related genes in colorectal tumors.Oncology letters · 2015Article
- Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomena.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2015Review
- Excess PLAC8 promotes an unconventional ERK2-dependent EMT in colon cancer.The Journal of clinical investigation · 2014Article
- P-cadherin signals through the laminin receptor α6β4 integrin to induce stem cell and invasive properties in basal-like breast cancer cells.Oncotarget · 2014Article
- Beyond E-cadherin: roles of other cadherin superfamily members in cancer.Nature reviews. Cancer · 2014Review
- P-cadherin promotes liver metastasis and is associated with poor prognosis in colon cancer.The American journal of pathology · 2011Article
- Wnt signalling in adenomas of familial adenomatous polyposis patients.British journal of cancer · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundColorectal adenomatous and, probably, hyperplastic polyp development requires epithelial remodelling and stratification, with loss of E-cadherin expression implicated in adenoma formation. We have shown that P-cadherin, normally expressed in stratified epithelia and placenta, is aberrantly expressed in disturbed epithelial architecture associated with colitis.
aims(i) To investigate the role of P-cadherin in colonic polyp formation. (ii) To ascertain whether expression of P-cadherin is independent of or correlated with expression of its associated proteins--E-cadherin, beta-catenin, and gamma-catenin. (iii) To determine if P-cadherin is functional regarding catenin binding in polyps.
methodsExpression and localisation of cadherins (E- and P-) and their associated catenins (beta- and gamma-) were determined in aberrant crypt foci (ACF), in polyps with hyperplastic morphology (hyperplastic polyps and serrated adenomas), and in adenomatous polyps by immunohistochemistry, western blotting, and mRNA in situ hybridisation. Assessment of cadherin-catenin binding was evaluated by co-immunoprecipitation. Adenomatous polyposis coli (APC) mutation was assessed in adenomatous polyps.
resultsP-cadherin was expressed from ACF through to hyperplastic and adenomatous polyps. Alterations in E-cadherin and catenin expression occurred later, with variant patterns in (i) ACF, (ii) hyperplastic polyps and serrated adenomas, and (iii) adenomatous polyps. P-cadherin present in adenomas was functional with regard to catenin binding, and its expression was independent of APC mutational status.
conclusionsP-cadherin is aberrantly expressed from the earliest morphologically identifiable stage of colonocyte transformation, prior to changes in E-cadherin, catenin, and APC expression/mutation. P-cadherin expression alone does not predict tissue morphology, and such expression is independent of that of associated cadherins and catenins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.